These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

656 related articles for article (PubMed ID: 26324507)

  • 21. Soluble fms-like tyrosine kinase-1 and soluble endoglin in HIV-associated preeclampsia.
    Govender N; Naicker T; Rajakumar A; Moodley J
    Eur J Obstet Gynecol Reprod Biol; 2013 Sep; 170(1):100-5. PubMed ID: 23806447
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Jumonji Domain Containing Protein 6 Is Decreased in Human Preeclamptic Placentas and Regulates sFLT-1 Splice Variant Production.
    Palmer KR; Tong S; Tuohey L; Cannon P; Ye L; Hannan NJ; Brownfoot FC; Illanes SE; Kaitu'u-Lino TJ
    Biol Reprod; 2016 Mar; 94(3):59. PubMed ID: 26819475
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of nicotine on the production of soluble fms-like tyrosine kinase-1 and soluble endoglin in human umbilical vein endothelial cells and trophoblasts.
    Kwon JY; Bai SW; Kwon YG; Kim SH; Kim CH; Kang MH; Linton JA; Park YW
    Acta Obstet Gynecol Scand; 2010; 89(4):565-571. PubMed ID: 20367431
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gadd45α as an upstream signaling molecule of p38 MAPK triggers oxidative stress-induced sFlt-1 and sEng upregulation in preeclampsia.
    Luo X; Yao ZW; Qi HB; Liu DD; Chen GQ; Huang S; Li QS
    Cell Tissue Res; 2011 Jun; 344(3):551-65. PubMed ID: 21519896
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vivo uteroplacental release of placental growth factor and soluble Fms-like tyrosine kinase-1 in normal and preeclamptic pregnancies.
    Holme AM; Roland MC; Henriksen T; Michelsen TM
    Am J Obstet Gynecol; 2016 Dec; 215(6):782.e1-782.e9. PubMed ID: 27503620
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preeclampsia is associated with the presence of transcriptionally active placental fragments in the maternal lung.
    Buurma AJ; Penning ME; Prins F; Schutte JM; Bruijn JA; Wilhelmus S; Rajakumar A; Bloemenkamp KW; Karumanchi SA; Baelde HJ
    Hypertension; 2013 Sep; 62(3):608-13. PubMed ID: 23817495
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Loss of Akt activity increases circulating soluble endoglin release in preeclampsia: identification of inter-dependency between Akt-1 and heme oxygenase-1.
    Cudmore MJ; Ahmad S; Sissaoui S; Ramma W; Ma B; Fujisawa T; Al-Ani B; Wang K; Cai M; Crispi F; Hewett PW; Gratacós E; Egginton S; Ahmed A
    Eur Heart J; 2012 May; 33(9):1150-8. PubMed ID: 21411816
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combining metformin and sulfasalazine additively reduces the secretion of antiangiogenic factors from the placenta: Implications for the treatment of preeclampsia.
    Brownfoot FC; Hastie R; Hannan NJ; Cannon P; Nguyen TV; Tuohey L; Cluver C; Tong S; Kaitu'u-Lino TJ
    Placenta; 2020 Jun; 95():78-83. PubMed ID: 32452405
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A wash step at collection of placental biopsies from preeclamptic pregnancies does not adversely affect levels of sFlt-1 or endoglin.
    Kaitu'u-Lino TJ; Hannan NJ; De Silva M; Binder N; Tuohey L; Cannon P; Tong S
    Pregnancy Hypertens; 2015 Oct; 5(4):294-7. PubMed ID: 26597743
    [TBL] [Abstract][Full Text] [Related]  

  • 30. YC-1 reduces placental sFlt-1 and soluble endoglin production and decreases endothelial dysfunction: A possible therapeutic for preeclampsia.
    Brownfoot FC; Tong S; Hannan NJ; Hastie R; Cannon P; Tuohey L; Kaitu'u-Lino TJ
    Mol Cell Endocrinol; 2015 Sep; 413():202-8. PubMed ID: 26159901
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Uteroplacental arterio-venous difference in soluble VEGFR-1 (sFlt-1), but not in soluble endoglin concentrations in preeclampsia.
    Paasche Roland MC; Lorentzen B; Godang K; Henriksen T
    Placenta; 2012 Mar; 33(3):224-6. PubMed ID: 22264588
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glyceryl trinitrate inhibits hypoxia-induced release of soluble fms-like tyrosine kinase-1 and endoglin from placental tissues.
    Barsoum IB; Renaud SJ; Graham CH
    Am J Pathol; 2011 Jun; 178(6):2888-96. PubMed ID: 21641407
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oxidative stress-induced Gadd45α inhibits trophoblast invasion and increases sFlt1/sEng secretions via p38 MAPK involving in the pathology of pre-eclampsia.
    Liu X; Deng Q; Luo X; Chen Y; Shan N; Qi H
    J Matern Fetal Neonatal Med; 2016 Dec; 29(23):3776-85. PubMed ID: 26809169
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transcription factors E2F1 and E2F3 are expressed in placenta but do not regulate MMP14.
    Kaitu'u-Lino TJ; Hastie R; Cannon P; Nguyen H; Lee S; Hannan NJ; Tong S
    Placenta; 2015 Aug; 36(8):932-7. PubMed ID: 26145228
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Resveratrol inhibits release of soluble fms-like tyrosine kinase (sFlt-1) and soluble endoglin and improves vascular dysfunction - implications as a preeclampsia treatment.
    Hannan NJ; Brownfoot FC; Cannon P; Deo M; Beard S; Nguyen TV; Palmer KR; Tong S; Kaitu'u-Lino TJ
    Sci Rep; 2017 May; 7(1):1819. PubMed ID: 28500309
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Procyanidin B2 ameliorates endothelial dysfunction and impaired angiogenesis via the Nrf2/PPARγ/sFlt-1 axis in preeclampsia.
    Liu L; Wang R; Xu R; Chu Y; Gu W
    Pharmacol Res; 2022 Mar; 177():106127. PubMed ID: 35150862
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Exosomes From Women With Preeclampsia Induced Vascular Dysfunction by Delivering sFlt (Soluble Fms-Like Tyrosine Kinase)-1 and sEng (Soluble Endoglin) to Endothelial Cells.
    Chang X; Yao J; He Q; Liu M; Duan T; Wang K
    Hypertension; 2018 Dec; 72(6):1381-1390. PubMed ID: 30571229
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diagnostic utility of soluble fms-like tyrosine kinase 1 and soluble endoglin in hypertensive diseases of pregnancy.
    Salahuddin S; Lee Y; Vadnais M; Sachs BP; Karumanchi SA; Lim KH
    Am J Obstet Gynecol; 2007 Jul; 197(1):28.e1-6. PubMed ID: 17618745
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Proton Pump Inhibitors Decrease Soluble fms-Like Tyrosine Kinase-1 and Soluble Endoglin Secretion, Decrease Hypertension, and Rescue Endothelial Dysfunction.
    Onda K; Tong S; Beard S; Binder N; Muto M; Senadheera SN; Parry L; Dilworth M; Renshall L; Brownfoot F; Hastie R; Tuohey L; Palmer K; Hirano T; Ikawa M; Kaitu'u-Lino T; Hannan NJ
    Hypertension; 2017 Mar; 69(3):457-468. PubMed ID: 28115513
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular mechanisms and therapeutic implications of the carbon monoxide/hmox1 and the hydrogen sulfide/CSE pathways in the prevention of pre-eclampsia and fetal growth restriction.
    Ahmed A
    Pregnancy Hypertens; 2014 Jul; 4(3):243-4. PubMed ID: 26104642
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.